Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria

monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in The Lancet Infectious Diseases by researchers at the University of Maryland School of Medicine (UMSOM).

Rapid Method Finds Potent COVID-19 Monoclonal Antibody Among a Trillion Possibilities

University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method – as well as a trio of successful animal studies on an antibody called “Ab1” – are described today in the Proceedings of the National Academy of Sciences. Ab1 is on track for human clinical trials by early next year.

Preclinical testing of inhaled monoclonal antibody for COVID-19 shows therapeutic efficacy

An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.

First Patients in NIH ACTIV-3 Clinical Trial Enroll in Dallas

On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.